BCG
CORT icon

Breakwater Capital Group’s Corcept Therapeutics CORT Stock Holding History

Breakwater Capital Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$315K Sell
2,732
-100
-4% -$10.8K 0.04% 314
2026
Q2 		$246K Buy
+2,832
New +$171K 0.03% 334

Other funds holding CORT

VFP
Vilga Financial Planning Fair Lawn, New Jersey $168M AUM 23.03% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
WPC
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
RA
Riversedge Advisors Wilmington, Delaware $813M AUM 18.09% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

Breakwater Capital Group's CORT Position: Q3 2026 in Review

Breakwater Capital Group reduced its Corcept Therapeutics (CORT) stake by 3.5% in Q3 2026, selling an estimated $10.8K and leaving 2,732 shares worth $315K. The position accounts for 0.04% of the portfolio, ranked #314.

Breakwater Capital Group first reported a position in CORT in Q2 2026 and has held it in 2 quarters since. 12 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Breakwater Capital Group held 2,732 shares of Corcept Therapeutics worth $315K as of Q3 2026.
  • Breakwater Capital Group sold 100 Corcept Therapeutics shares in Q3 2026, an estimated $10.8K.
  • Corcept Therapeutics made up 0.04% of Breakwater Capital Group's portfolio in Q3 2026, its #314 holding.
  • Breakwater Capital Group first reported a position in Corcept Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 12 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Breakwater Capital Group's 13F filing for Q3 2026, filed 9 Oct 2026.